inspired science to
Address the Needs of Patients

We are applying our scientific leadership in the kallikrein-kinin system and oral drug discovery to develop oral protease inhibitor medicines for patients with diseases caused by the proteases plasma kallikrein and Factor XIIa.

Our science

Our pipeline

Our publications & posters

Sebetralstat

Sebetralstat is our on-demand HAE investigational product.

See Our Phase 3 Data
   for Sebetralstat

our Clinical trials

KalVista is focused on developing new oral treatments for HAE.

Learn more about
   clinical stuides

our educational website
Mind the HAE Attack

We’re not just developing drugs for HAE; we also care about the patient journey. We invite healthcare professionals to visit Mind The HAE Attack to learn more about the perspectives and experiences of patients and their views about on-demand treatment to manage HAE.

VISIT MindTheHAEAttack.com
   TO LEARN MORE

Medical information

Contact for Medical Information

If you have questions, our clinical team would be happy to speak with you. Please contact us either by phone or email at:

+1 (857) 999-0075 medinfo@kalvista.com

Expanded Access to
Investigational medicines